- HDAC6: A unique HDAC family member as a cancer target
Sumeet Kaur et al, 2022, Cellular Oncology CrossRef - Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma
Huimin Lei et al, 2022, Frontiers in Oncology CrossRef - TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
Akiko Arimura et al, 2024, Cancers CrossRef - HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis
Lihong Yang et al, 2024, BMC Cancer CrossRef - Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe
Rahman Ud Din et al, 2023, International Journal of Molecular Sciences CrossRef - Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
Husvinee Sundaramurthi et al, 2022, International Journal of Molecular Sciences CrossRef - Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
Hyein Jo et al, 2022, International Journal of Molecular Sciences CrossRef - Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
Jianglei Li et al, 2022, Frontiers in Pharmacology CrossRef